Acknowledgments
Thanks to the company Diasorin® for providing us with the necessary reagents for this study.
-
Research ethics: The investigator has signed a commitment to comply with Reference Methodology n°004 issued by French Authorities (CNIL). The raw data supporting the conclusions of this article will be made available by the authors within respect of General Data Protection Regulation, without undue reservation. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).
-
Informed consent: The subjects were all informed and did not oppose; written consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
-
Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission. Blandine Billet: Methodology, Supervision, Validation, Data curation, Writing – original draft, Writing – review & editing; Luc Choisnard: Data curation, Formal analysis, Writing – review & editing. Patrice Faure: Funding acquisition, Supervision, Writing – review; Denis Guicherd: Methodology, Investigation; Elodie Cussigh: Methodology, Investigation; Eric Peyrin: Supervision, Writing – review; Corinne Ravelet: Supervision, Writing – review; Benoit Chovelon: Conceptualization, Project administration, Methodology, Supervision, Validation, Data curation, Writing – review & editing.
-
Competing interests: The authors state no conflict of interest.
-
Research funding: This work was supported by the Agence Nationale de la Recherche (ANR) LabEx “Arcane” (ANR-11-LABX-0003-01) and CBH-EUR-GS (ANR-17-EURE-0003).
-
Data availability: The raw data can be obtained on request from the corresponding author.
References
1. Ricciuto, A, Griffiths, AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307–20. https://doi.org/10.1080/10408363.2019.1619159.Search in Google Scholar PubMed
2. Walsham, NE, Sherwood, RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol 2016;9:21–9. https://doi.org/10.2147/ceg.s51902.Search in Google Scholar PubMed PubMed Central
3. LIAISON® Calprotectin ([REF] 318960) EN – 54427 – 2021-03). Stillwater. MN 55082, USA: DiaSorin Inc.Search in Google Scholar
4. Wobbrock, JO, Findlater, L, Gergle, D, Higgins, JJ. The aligned rank transform for nonparametric factorial analyses using only ANOVA procedures. In: Proceedings of the SIGCHI conference on human factors in computing systems. Association for Computing Machinery, New York, NY, USA; 2011:143–6 pp.10.1145/1978942.1978963Search in Google Scholar
5. Kay, M, Elkin, L, Higgins, J, Wobbrock, J. ARTool: aligned rank transform for nonparametric factorial ANOVAs. R package version 0.11.1. 2021. https://github.com/mjskay/ARTool.Search in Google Scholar
6. R Core Team. R Core Team. (2022). R: a language and environment for statistical computing. In: R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. https://www.R-project.org/.Search in Google Scholar
7. Oddoze, C, Lombard, E, Portugal, H. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem 2012;45:464–9. https://doi.org/10.1016/j.clinbiochem.2012.01.012.Search in Google Scholar PubMed
8. Petersen, PH, Fraser, CG, Lund, F, Sölétormos, G. Confirmation of analytical performance characteristics required for the reference change value applied in patient monitoring. Scand J Clin Lab Investig 2015;75:628–30. https://doi.org/10.3109/00365513.2015.1057897.Search in Google Scholar PubMed
9. Padoan, A, D’Incà, R, Scapellato, ML, Bastiani, RD, Caccaro, R, Mescoli, C, et al.. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin Chem Lab Med 2018;56:1926–35. https://doi.org/10.1515/cclm-2018-0134.Search in Google Scholar PubMed
© 2023 Walter de Gruyter GmbH, Berlin/Boston
